Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Net Margin (2016 - 2025)

Historic Net Margin for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to 112.81%.

  • Ultragenyx Pharmaceutical's Net Margin fell 170900.0% to 112.81% in Q3 2025 from the same period last year, while for Sep 2025 it was 92.17%, marking a year-over-year increase of 147700.0%. This contributed to the annual value of 101.84% for FY2024, which is 378600.0% up from last year.
  • Ultragenyx Pharmaceutical's Net Margin amounted to 112.81% in Q3 2025, which was down 170900.0% from 69.04% recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's 5-year Net Margin high stood at 69.04% for Q2 2025, and its period low was 270.23% during Q3 2022.
  • Moreover, its 5-year median value for Net Margin was 140.76% (2021), whereas its average is 136.27%.
  • The largest annual percentage gain for Ultragenyx Pharmaceutical's Net Margin in the last 5 years was 1908400bps (2021), contrasted with its biggest fall of -1817900bps (2021).
  • Ultragenyx Pharmaceutical's Net Margin (Quarter) stood at 149.65% in 2021, then decreased by 0bps to 150.13% in 2022, then skyrocketed by 36bps to 96.7% in 2023, then rose by 15bps to 81.73% in 2024, then tumbled by -38bps to 112.81% in 2025.
  • Its Net Margin stands at 112.81% for Q3 2025, versus 69.04% for Q2 2025 and 108.46% for Q1 2025.